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Acetylcholine-responsive cargo release using 
acetylcholinesterase-capped nanomaterials 
Tania M. Godoy-Reyes,abc Antoni Llopis-Lorente,abd Alba García-Fernández,abd Pablo Gaviña,abc Ana 
M. Costero,abc* Ramón Martínez- Máñez,abd* and Félix Sancenónabd 
 
Mesoporous silica nanoparticles capped with acetylcholinesterase, 
through boronic ester linkages, selectively release an entrapped 
cargo in the presence of acetylcholine.  
 
Acetylcholine (ACh) is one of the most important 
neurotransmitters in the central nervous system (CNS) and in 
the peripheral nervous system (PNS).1 ACh is synthesized in 
neuron terminals by acetylation of choline with acetyl 
coenzyme A in a reaction catalysed by the enzyme choline 
acetyltransferase.2 In the CNS, ACh is responsible for 
modulating the activity of the neurons which control 
motivation, excitement and attention.3 It is a key 
neurotransmitter to maintain memory and promote learning, in 
addition to favour brain neuroplasticity.4 On the other hand in 
the PNS, ACh is responsible for transmitting signals between 
motor nerves and muscles, contributing to the contraction of 
the cardiac, skeletal and smooth muscles.5 Low levels of ACh are 
related to neurodegenerative pathologies such as Alzheimer,6 
and myasthenia gravis.7 In contrast, high levels of ACh are 
responsible for movement disorders such as dystonia8 and 
Parkinson’s disease.9 The high concentrations of ACh in the 
movement disorders are caused by an imbalance between 
cholinergic and dopaminergic activity, generating a dopamine 
depletion which blocks the autoinhibition of acetylcholine 
release through muscarinic autoreceptors, leading to excessive 
acetylcholine release to the synaptic cleft.10 
From another point of view, the design of smart delivery 
systems able to release an entrapped cargo in response to a 
specific stimulus is receiving increasing attention in recent 
years.11 For the development of these smart delivery systems 
inorganic scaffolds, liposomes, polymers and metallic 
nanoparticles are commonly used as nanocarriers.12 Among 
them, mesoporous silica (MS) scaffolds offer appealing features 
such as high loading capacity, uniform pore distribution, 
biocompatibility, thermal stability, easy synthesis, tuneable size 
and easy functionalization.13 Additionally, the external surface 
of the loaded MS scaffold can be functionalized with molecular 
or (supra)molecular architectures which change their shape 
and/or size upon application of external stimuli.14 In the 
absence of stimuli pores are blocked preventing cargo release 
whereas in their presence a marked delivery is observed. Gated 
MS materials that respond to physical and (bio)chemical stimuli 
have been developed.15 Notwithstanding, the design of gated 
materials that respond to small biomolecules remains more 
challenging and comparatively fewer examples have been 
reported.16 
Given the relevance of ACh as a key neurotransmitter and 
our interest in the development of stimuli-responsive gated 
materials for biomedical applications, we present herein a 
simple strategy to design ACh-responsive delivery systems 
based on the use of the enzyme acetylcholinesterase. 
Acetylcholinesterase is a glycoprotein that catalyses the 
breakdown of acetylcholine at the synaptic cleft. In our 
approach, acetylcholinesterase plays the following roles: (i) acts 
as capping agent, anchored to the external surface of the 
support through the formation of hydrolysable phenylboronic 
esters; (ii) acts as recognition unit, capable of detecting Ach; (iii) 
acts as anticholinergic agent by breaking down ACh, and, finally, 
(iv) acts as mediator agent, that generates acid molecules which 
induce the uncapping of the support. As a support, we have 
used MS nanoparticles that are loaded with a fluorescent cargo 
([Ru(bpy)3]Cl2) and functionalized with phenylboronic acid 
residues on the external surface. Oligosaccharide groups of the 
enzyme are linked to phenylboronic acid residues by the 
formation of boronic acid cyclic esters, a well-known strategy 
previously used for the immobilisation of glycoproteins on 
electrodes and surfaces.17 Acetylcholinesterase induces the 
rupture of ACh into choline and acetic acid. The later induces 
the hydrolysis of acid-sensitive boronic esters and the 
uncapping of the pores, resulting in cargo release (Scheme 1). 
To prepare the ACh-responsive nanodevice, MS 
nanoparticles were synthesised via a sol-gel template method 
(solid S0). S0 was suspended in acetonitrile and treated with (3-
glycidyloxypropyl)trimethoxysilane for 5.5 h. Then, 3-
aminophenylboronic acid was anchored by nucleophilic attack 
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of the amine to the highly reactive epoxide on the silica surface. 
The pores were loaded with the fluorescent dye [Ru(bpy)3]Cl2 as 
a model cargo (S1). S1 was finally capped with 
acetylcholinesterase, via the formation of cyclic phenylboronic 
acid esters between the oligosaccharide chains of the 
glycoenzyme and the phenylboronic groups on the 
nanoparticles surface, yielding S2. 
 
Scheme 1. Representation of the design and performance of the acetylcholinesterase-
capped nanodevice S2 for cargo release in response to ACh. 
The prepared materials were characterised by different 
standard techniques. Powder X-ray diffraction (PXRD) of the as-
made nanoparticles showed the (100) low-angle reflection 
Bragg peak at around 2.2° which is characteristic of MCM-41-
type porous materials, with a slight displacement to 2.4° after 
surfactant removal (Figure 1A). The presence of this peak in the 
PXRD pattern of S1 confirmed that the functionalization and 
loading processes had not damaged the mesoporous 3-D 
structure. From N2 adsorption-desorption isotherms (Figure 
1B), pore volume and pore size S0 were determined as 0.715 
cm3 g-1 and 2.52 nm, respectively, by applying the BJH model18 
on the absorption branch of the isotherm. The volume of N2 
adsorbed considerably decreased from the empty solid S0 to 
the loaded nanoparticles S1 due to the filling of the pores with 
the cargo. A large specific surface area of 1141.13 m2 g−1 was 
determined for S0 according to the BET model,19 whereas it 
reduced to 20.46 m2 g−1 for S1. Transmission electron 
microscopy (TEM) images of S0, S1 and S2 confirmed the 
formation of nanoparticles (average diameter of 92±10 nm) 
with spherical morphology and porous structure, that was 
preserved after the functionalization processes (Figure 1C). 
Additionally, the surface modification was confirmed by 
chemical methods such as solid-state 13C-NMR, 11B-NMR, FTIR, 
and UV-visible (see Figure SI-1-4). The zeta potential of the 
starting S0 nanoparticles was -30.5 mV and decreased to -12.7 
mV for S1 due to its functionalization with phenylboronic acid 
residues. For the final nanodevice S2, the surface charge 
increased (-24.1 mV) compared to S1 as a consequence of 
enzyme capping (Figure SI-5). The hydrodynamic diameter of 
the final nanodevice S2 was determined to be 152 nm using 
dynamic light scattering (DLS) measurements (Figure SI-6). 
Besides, the content of grafted aminophenylboronic moiety (53 
mg per g of solid) and [Ru(bpy)3]Cl2 (270 mg per g of solid) on S1 
were estimated by elemental analysis. The boron and 
ruthenium content were determined by ICP-mass spectroscopy 
and amounted to 5.10±0.03 and 44.7±0.3 mg per g of S1, 
respectively. Moreover, the immobilization of 
acetylcholinesterase on S2 was confirmed by a specific 
enzymatic assay (Figure SI-7). Additionally, the amount of 
protein was quantified as 58.5 mg per g of S2 according to the 
Bradford method. The key role played by the phenylboronic 
linker in the attachment of the enzyme was confirmed by 
control experiments using non-functionalized MS nanoparticles 
(see SI, Section 9). The total loaded [Ru(bpy)3]Cl2 dye in the final 
nanodevice S2 was 34 mg g-1 (determined via several 
extractions of the dye content in water at pH 3, and 
spectrophotometric measurement). Finally, Figure 1D shows 
scanning transmission electron microscopy coupled with energy 
dispersive X-ray spectroscopy (STEM-EDX) mapping of several 
elements on the final nanodevice S2 attributed to the different 
components: Si and O (silica scaffold), C and N (cargo, 
aminophenylboronic moiety and enzyme), B (boronic ester), 
and S (cysteine groups of the enzyme). 
 
Figure 1. A) PXRD of (a) as-made MS nanoparticles, (b) calcined support S0, and (c) 
loaded and functionalized nanoparticles S1. B) N2 adsorption-desorption isotherm for (a) 
S0 and (b) S1 nanoparticles. C) TEM images of (a) S0, (b) S1, and (c) final nanodevice S2. 
D) STEM image and STEM-EDX mapping of different atoms on the final nanodevice S2. 
Once characterized, cargo release from S2 was evaluated in 
aqueous media in the absence and presence of ACh. In a typical 
release experiment, aqueous (pH 7.5, 20 mM Na2SO4) S2 
suspensions (2 mg mL-1) in the absence and in the presence of 
ACh (1 mM) were shaken at room temperature. Aliquots were 
taken at different times, centrifuged (to eliminate the 
nanoparticles), and the amount of cargo released to the 
solution was assessed by measuring the emission band of 
[Ru(bpy)3]Cl2 at 595 nm (λexc=435 nm). The obtained delivery 
kinetics profiles are shown in Figure 2. In the absence of ACh, 








Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name .,  2013, 00 , 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
capping of the nanoparticles. On the contrary, in the presence 
of ACh, a remarkable and fast delivery of the payload was 
observed in less than 5 minutes, which could be appreciated 
even to the naked eye (Figure SI-11). This fast and effective 
response is attributed to the rapid action of 
acetylcholinesterase (turnover number=7.4 x 105 min-1)20 which 
is an enzyme naturally prepared to catalyse very fast in order to 
regulate muscle contraction and synaptic transmission in the 
nervous system. ACh is hydrolysed by the enzyme into choline 
and acetic acid (pKa=4.75),21 which triggers the rupture of the 
acid-sensitive boronic cyclic esters and results in the 
detachment of the enzyme and the delivery of the payload. A 
reduction in the pH of the solution was observed after release 
experiment in the presence of ACh, thus confirming the 
formation of acetic acid (Figure SI-15). Furthermore, in order to 
confirm enzyme detachment from the nanoparticles surface, 
we measured the acetylcholinesterase activity on S2 after ACh-
triggered release and it decreased to 0.4 U mg-1 (4.5 U mg-1 for 
the control sample) (Figure SI-12). In further control 
experiments, we confirmed that the release from S2 is triggered 
at acidic pH (4.5). However, S2 remained capped at slightly 
acidic pH (6.5) such as the one found in tumours and some 
intracellular compartments (Figures SI-16-17).22 On the other 
hand, release experiments with S1 (without the enzyme) in the 
presence and absence of ACh were also carried out. The 
obtained results (Figure SI-18) showed a marked cargo release 
in both cases. This confirms the key role played by the enzyme 
on the performance of the nanodevice. 
 
Figure 2. Kinetics of cargo release from S2 (2 mg mL-1) in aqueous media (pH 7.5) 
in the presence of ACh (1 mM, red curve) and absence of ACh (black curve) 
determined by measuring [Ru(bpy)3]Cl2 fluorescence at 595 nm (λexc= 453 nm). 
Error bars correspond to the s. d. from three independent experiments.  
In order to assess the selectivity of the nanodevice, we 
evaluated the response of aqueous suspensions of S2 (2 mg mL-
1) in the presence of other relevant neurotransmitters such as 
epinephrine (Epy), norepinephrine (NE), dopamine (DA), 
serotonin (5‐HT), γ‐aminobutyric acid (GABA), glutamate (Glu), 
asparate (Asp), and glycine (Gly) at 1 mM concentration. The 
obtained emission intensities at 595 nm (due to [Ru(bpy)3]Cl2 
release) after 10 min are shown in Figure 3. As could be seen, 
S2 nanodevice remained closed in the presence of these 
neurotransmitters whereas a selective cargo release occurred 
only in the presence of ACh, suggesting than S2 could be used 
for the selective detection of ACh.  
In order to evaluate the sensitivity of the nanodevice, S2 
nanoparticles were exposed to different concentrations of ACh 
and the released cargo at a fixed time (10 min) was measured. 
As can be observed in Figure SI-10, the amount of cargo release 
was very low at acetylcholine concentrations below 25 µM, 
whereas a significant and proportional increase occurred in the 
0.025─10 mM concentration range. This indicates that S2 would 
remain closed in blood, where the concentration of ACh is 
around 9 nM.23 In contrast, in patients suffering from 
Parkinson’s disease the levels of ACh in synaptic vesicles, 
neuromuscular junctions and synaptic clefts are higher than 100 
mM, 3 mM and 0.5 mM respectively,23 suggesting than S2 
nanoparticles could be able to release the cargo in these target 
regions. 
 
Figure 3. Cargo release from S2 (2 mg mL-1) in aqueous media (pH 7.5) in the 
presence of selected neurotransmitters (1 mM) after 10 min. 
Finally, we aimed to demonstrate that this delivery system 
could operate in more complex biological environments. To this 
end, we prepared S2dox, a solid like S2 but loaded with the 
cytotoxic drug doxorubicin. The amount of loaded doxorubicin 
was quantified as 195 mg per g of S2dox by spectrophotometry, 
with a release efficiency of ca. 31% in in vitro release 
experiments conducted in a similar way as describe above 
(Figure SI-20). Next, as a proof of concept, human HeLa cell24 
culture media (DMEM supplemented with 10% FBS)25 were 
treated with 50 µg mL-1 of S2dox for 30 min, washed to remove 
non-internalized particles and further incubated for 24 h in the 
absence or presence of ACh (50 mM). After 24 h of incubation, 
cell viability was determined by means of the WST-1 cell 
proliferation reagent. Cell viability remained nearly to 100% in 
the presence of ACh or in the presence of S2dox, whereas it 
reduced to 72% upon treatment with the equivalent amount of 
free doxorubicin (Figure 4A). Remarkably, a significant 
reduction in cell viability (ca. 40%) was observed in the 
simultaneous presence of both, S2dox and ACh, which was 
ascribed to the recognition of the neurotransmitter by the 
nanodevice and the subsequent release of the drug. 
Additionally, release of doxorubicin in cells was directly 
visualized by means of confocal microscopy imaging. For these 
experiments, cells were incubated with S2dox for 2 h in the 
absence or presence of ACh, washed to remove non-
internalized particles and stained with DNA marker Hoechst 
3342 (blue). A clear doxorubicin-associated fluorescence (red) 
was observed for cells treated with S2dox in a culture media 
containing ACh (Figure 4B). These results confirm the ability of 
the nanodevice to recognise ACh and deliver the payload 
despite the presence of cellular metabolites and other potential 
interferences found in cell culture media.  
In conclusion, we report herein the design, synthesis and 
characterization of ACh-responsive delivery nanocarriers, based on 
the use of MS nanoparticles capped with the enzyme 
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acetylcholinesterase using boronic ester linkers. In the presence of 
ACh, the neurotransmitter is detected by acetylcholinesterase and 
transformed into choline and acetic acid, which leads to the 
hydrolysis of boronic cyclic esters, the subsequent detachment of the 
enzyme and the uncapping of pores. The nanoparticles show a 
remarkable payload delivery in the presence of ACh in less than 5 
min, whereas release is negligible in the absence of the 
neurotransmitter. Moreover, the nanodevice remains closed in the 
presence of other relevant neurotransmitters and responds 
selectively to ACh. Cargo release is negligible at ACh concentrations 
present in human blood, whereas a significant payload delivery is 
observed in the 0.025-10 mM range, which coincides with typical 
concentration of ACh in synaptic vesicles, neuromuscular junctions 
and synaptic clefts in Parkinson's patients. We also demonstrate that 
the nanodevice shows an ACh-responsive behaviour in complex 
biological environments such as HeLa cells. We hope this study could 
inspire the development of smart nanosensors able to selectively 
detect ACh and/or nanocarriers for therapies with high effectiveness 
and minimal side effects for the future treatment of nervous system 
disorders such as Parkinson’s. 
 
 
Figure 4. Experiments in cell culture media (DMEM supplemented with 10% FBS). 
A) HeLa cell viability for the control experiment (no ACh and no S2dox), incubation 
with ACh (50 mM), incubation with S2dox (50 μg mL−1), incubation with the 
equivalent amount of free doxorubicin, and incubation with both ACh and S2dox. 
Error bars correspond to the s. d. from three independent experiments containing 
triplicates. B) Confocal microscopy images of HeLa cells (showing nuclei-marker 
fluorescence in blue) for: (a) control experiment, (b) cells incubated with S2dox, 
and (c) cells incubated with S2dox in a medium containing ACh showing 
doxorubicin-associated fluorescence in red.  
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